United States· US:0074-1065_5c5b86a4-65e0-4197-87fd-4b6024e66587
Skyrizi
A medicinal product, registered in United States by AbbVie Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Manufacturer
- AbbVie Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 26, 2026
Packs & prices · 2
- ndc110074-1065-01
- ndc110074-1065-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe683210-b897-4556-8008-9476f8960322 GET /v1/drugs/fe683210-b897-4556-8008-9476f8960322?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": null,
"substance": null,
"productndc": "0074-1065",
"dosage_form": "KIT",
"dea_schedule": null,
"strength_unit": null,
"application_number": "BLA761105",
"marketing_category": "BLA"
}See everything about Skyrizi.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.